Oppenheimer Asset Management Inc. Has $407,000 Stock Position in Glaukos Corporation (NYSE:GKOS)

Oppenheimer Asset Management Inc. cut its holdings in Glaukos Corporation (NYSE:GKOS - Free Report) by 52.2% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,137 shares of the medical instruments supplier's stock after selling 4,521 shares during the quarter. Oppenheimer Asset Management Inc.'s holdings in Glaukos were worth $407,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in GKOS. Whipplewood Advisors LLC boosted its stake in shares of Glaukos by 3,957.1% in the 1st quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock valued at $28,000 after purchasing an additional 277 shares during the last quarter. Versant Capital Management Inc lifted its holdings in Glaukos by 583.9% in the first quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock valued at $38,000 after buying an additional 327 shares during the period. IFP Advisors Inc bought a new position in Glaukos in the fourth quarter valued at approximately $43,000. CoreCap Advisors LLC grew its holdings in Glaukos by 36.4% during the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock worth $112,000 after acquiring an additional 200 shares during the period. Finally, Picton Mahoney Asset Management acquired a new stake in Glaukos during the 4th quarter worth $125,000. 99.04% of the stock is owned by institutional investors.

Glaukos Trading Down 0.1%

Glaukos stock traded down $0.13 during trading hours on Thursday, reaching $103.50. 289,937 shares of the company's stock were exchanged, compared to its average volume of 924,479. The firm's 50 day simple moving average is $95.54 and its 200 day simple moving average is $116.52. Glaukos Corporation has a twelve month low of $77.10 and a twelve month high of $163.71. The company has a quick ratio of 5.62, a current ratio of 6.49 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $5.91 billion, a PE ratio of -43.67 and a beta of 0.82.

Glaukos (NYSE:GKOS - Get Free Report) last announced its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.11. The company had revenue of $106.66 million for the quarter, compared to analyst estimates of $102.78 million. Glaukos had a negative return on equity of 10.66% and a negative net margin of 31.40%. The firm's revenue for the quarter was up 24.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.70) EPS. Research analysts predict that Glaukos Corporation will post -1.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on GKOS shares. Morgan Stanley decreased their price target on shares of Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Truist Financial reiterated a "buy" rating and set a $135.00 target price (down from $140.00) on shares of Glaukos in a report on Thursday, May 1st. Stephens lowered their price target on Glaukos from $140.00 to $115.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Wells Fargo & Company lowered Glaukos from an "overweight" rating to an "equal weight" rating and dropped their price target for the stock from $160.00 to $86.00 in a research report on Thursday, May 1st. Finally, Stifel Nicolaus decreased their price objective on Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, Glaukos presently has a consensus rating of "Moderate Buy" and an average price target of $134.67.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.